IGPR-1 regulates angiogenesis and endothelial barrier function (15, 16), decreases sensitivity of tumor cells to the genotoxic agent doxorubicin, and supports tumor cell survival in response to anoikis (17). The gene discussed is TMIGD2; the disease is neoplasm.